Cargando…
Glutamate Systems in DSM-5 Anxiety Disorders: Their Role and a Review of Glutamate and GABA Psychopharmacology
Serotonin reuptake inhibitors and benzodiazepines are evidence-based pharmacological treatments for Anxiety Disorders targeting serotonin and GABAergic systems, respectively. Although clearly effective, these medications fail to improve anxiety symptoms in a significant proportion of patients. New i...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7710541/ https://www.ncbi.nlm.nih.gov/pubmed/33329087 http://dx.doi.org/10.3389/fpsyt.2020.548505 |
_version_ | 1783617967954591744 |
---|---|
author | Nasir, Madeeha Trujillo, Daniel Levine, Jessica Dwyer, Jennifer B. Rupp, Zachary W. Bloch, Michael H. |
author_facet | Nasir, Madeeha Trujillo, Daniel Levine, Jessica Dwyer, Jennifer B. Rupp, Zachary W. Bloch, Michael H. |
author_sort | Nasir, Madeeha |
collection | PubMed |
description | Serotonin reuptake inhibitors and benzodiazepines are evidence-based pharmacological treatments for Anxiety Disorders targeting serotonin and GABAergic systems, respectively. Although clearly effective, these medications fail to improve anxiety symptoms in a significant proportion of patients. New insights into the glutamate system have directed attention toward drugs that modulate glutamate as potential alternative treatments for anxiety disorders. Here we summarize the current understanding of the potential role of glutamate neurotransmission in anxiety disorders and highlight specific glutamate receptors that are potential targets for novel anxiety disorder treatments. We also review clinical trials of medications targeting the glutamate system in DSM-5 anxiety disorders. Understanding the role of the glutamate system in the pathophysiology of anxiety disorder may aid in developing novel pharmacological agents that are effective in treating anxiety disorders. |
format | Online Article Text |
id | pubmed-7710541 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-77105412020-12-15 Glutamate Systems in DSM-5 Anxiety Disorders: Their Role and a Review of Glutamate and GABA Psychopharmacology Nasir, Madeeha Trujillo, Daniel Levine, Jessica Dwyer, Jennifer B. Rupp, Zachary W. Bloch, Michael H. Front Psychiatry Psychiatry Serotonin reuptake inhibitors and benzodiazepines are evidence-based pharmacological treatments for Anxiety Disorders targeting serotonin and GABAergic systems, respectively. Although clearly effective, these medications fail to improve anxiety symptoms in a significant proportion of patients. New insights into the glutamate system have directed attention toward drugs that modulate glutamate as potential alternative treatments for anxiety disorders. Here we summarize the current understanding of the potential role of glutamate neurotransmission in anxiety disorders and highlight specific glutamate receptors that are potential targets for novel anxiety disorder treatments. We also review clinical trials of medications targeting the glutamate system in DSM-5 anxiety disorders. Understanding the role of the glutamate system in the pathophysiology of anxiety disorder may aid in developing novel pharmacological agents that are effective in treating anxiety disorders. Frontiers Media S.A. 2020-11-19 /pmc/articles/PMC7710541/ /pubmed/33329087 http://dx.doi.org/10.3389/fpsyt.2020.548505 Text en Copyright © 2020 Nasir, Trujillo, Levine, Dwyer, Rupp and Bloch. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Psychiatry Nasir, Madeeha Trujillo, Daniel Levine, Jessica Dwyer, Jennifer B. Rupp, Zachary W. Bloch, Michael H. Glutamate Systems in DSM-5 Anxiety Disorders: Their Role and a Review of Glutamate and GABA Psychopharmacology |
title | Glutamate Systems in DSM-5 Anxiety Disorders: Their Role and a Review of Glutamate and GABA Psychopharmacology |
title_full | Glutamate Systems in DSM-5 Anxiety Disorders: Their Role and a Review of Glutamate and GABA Psychopharmacology |
title_fullStr | Glutamate Systems in DSM-5 Anxiety Disorders: Their Role and a Review of Glutamate and GABA Psychopharmacology |
title_full_unstemmed | Glutamate Systems in DSM-5 Anxiety Disorders: Their Role and a Review of Glutamate and GABA Psychopharmacology |
title_short | Glutamate Systems in DSM-5 Anxiety Disorders: Their Role and a Review of Glutamate and GABA Psychopharmacology |
title_sort | glutamate systems in dsm-5 anxiety disorders: their role and a review of glutamate and gaba psychopharmacology |
topic | Psychiatry |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7710541/ https://www.ncbi.nlm.nih.gov/pubmed/33329087 http://dx.doi.org/10.3389/fpsyt.2020.548505 |
work_keys_str_mv | AT nasirmadeeha glutamatesystemsindsm5anxietydisorderstheirroleandareviewofglutamateandgabapsychopharmacology AT trujillodaniel glutamatesystemsindsm5anxietydisorderstheirroleandareviewofglutamateandgabapsychopharmacology AT levinejessica glutamatesystemsindsm5anxietydisorderstheirroleandareviewofglutamateandgabapsychopharmacology AT dwyerjenniferb glutamatesystemsindsm5anxietydisorderstheirroleandareviewofglutamateandgabapsychopharmacology AT ruppzacharyw glutamatesystemsindsm5anxietydisorderstheirroleandareviewofglutamateandgabapsychopharmacology AT blochmichaelh glutamatesystemsindsm5anxietydisorderstheirroleandareviewofglutamateandgabapsychopharmacology |